U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07631871) titled 'An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy' on June 02.
Brief Summary: The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg/kg per cycle.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Neoplasms
Solid Tumors
HER2 Positive Solid T...